Last updated: February 24, 2026
What Is NDC 00574-0294?
NDC 00574-0294 identifies Albuterol Sulfate Inhalation Aerosol, 90 mcg. This inhaler medication is used for the management of bronchospasm in conditions such as asthma and COPD. It is a generic form of albuterol, a bronchodilator delivering quick relief from bronchospasm symptoms.
Market Dynamics
Market Size and Growth
The global asthma and COPD treatment market was valued at approximately USD 15.2 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 4.8% through 2030 [1].
Within this, albuterol inhalers represent a significant share reflecting the high prevalence of asthma and COPD. The U.S. accounts for around 45% of the global market, driven by extensive insurance coverage and the high prevalence rate of respiratory disorders [2].
Key Competitors
The inhaler market includes both brand and generic products:
| Product Name |
Manufacturer |
Market Share (estimated) |
Notes |
| Ventolin HFA |
GlaxoSmithKline |
60% |
Market leader, branded version of albuterol |
| ProAir HFA |
Teva |
20% |
Significant share, increased generic entry |
| Albuterol Sulfate Inhaler |
Multiple generics |
15% |
Growing due to patent expiration of brands |
| Others |
Various |
5% |
Includes specific generics and regional brands |
Pricing and reimbursement policies influence competitive positioning heavily.
Price Trends and Projections
Current Pricing Landscape
The average retail price for inhalers like Ventolin HFA is roughly USD 30–40 per inhaler unit. Generic formulations, including NDC 00574-0294, typically retail between USD 15–25, depending on pharmacy and insurance coverage [3].
Price Trends
Over the past five years, generic inhalers have seen:
- A decline of approximately 20% in retail prices due to increased market entry.
- Market share shifts favoring generics, especially with patent expirations of brand products in 2018–2020.
- Increased insurance coverage leading to customer preference for lower-cost generics.
Future Price Projections (Next 3–5 Years)
- Prices are expected to stabilize around USD 10–20 per inhaler for high-volume generics, driven by economies of scale and competitive pressures.
- Further reductions may occur if new generics enter the market or if formulary preferences shift towards suppliers offering lower-cost options.
- Price escalation risk remains limited, as insurers and healthcare systems seek cost containment.
Influencing Factors
- Patent expiration timelines for branded albuterol products: Major patents expired between 2018 and 2020 [4].
- Regulatory approvals: Increase in FDA approvals of generic albuterol inhalers accelerates price competition.
- Insurance formulary positioning: Favoring lower-cost generics can drive prices downward.
Regulatory and Policy Impact
The FDA's 2014 final guidance on inhaler generics facilitated faster approval pathways for inhalation drug devices and increased market penetration of generics [5].
State-level policies promoting generic substitution further accelerate price reductions.
Summary Metrics
| Aspect |
Data |
| Market Size (2022) |
USD 15.2 billion |
| CAGR (2023–2030) |
4.8% |
| Price per inhaler (generic) |
USD 10–20 (projected 2023–2028) |
| Market share of generics |
Approx. 15–20% (growing) |
| Patent expiration (brands) |
2018–2020 for major brands |
Key Takeaways
- NDC 00574-0294, as a generic inhaler, operates in a large and growing respiratory market.
- Price erosion has stabilized at low levels; further declines are possible with increased competition.
- Overall market growth is driven by the rising prevalence of respiratory conditions and generic proliferation.
- Regulatory pathways and insurance policies will continue to influence pricing trends.
- Despite competitive pressures, profit margins for generics will remain constrained due to price sensitivity and high competition.
FAQs
Q1: How does NDC 00574-0294 compare to brand-name inhalers in price?
A1: Generic inhalers like NDC 00574-0294 typically cost USD 10–20 per unit, compared to USD 30–40 for brand-name options like Ventolin HFA.
Q2: What is the outlook for the generic inhaler market over the next five years?
A2: Market share for generics will increase as patents expire and regulatory barriers lower, but prices will likely remain stable or decline slightly due to ongoing competition.
Q3: How do insurance policies affect prices for NDC 00574-0294?
A3: Insurance formularies favor lower-cost generics, which can lead to discounts and lower out-of-pocket costs for consumers.
Q4: Are there regulatory risks that could raise or lower prices?
A4: Regulatory approvals of new generics lower prices, while new patent filings could restrict generic entry temporarily.
Q5: What factors most influence the competitive positioning of NDC 00574-0294?
A5: Factors include manufacturing costs, FDA approval speed, insurance formulary inclusion, and the presence of competing generic brands.
References
- GlobalData. (2022). Market size and forecast for respiratory drugs. Global Respiratory Market Report.
- IQVIA. (2022). U.S. respiratory inhaler market data.
- GoodRx. (2023). Inhaler pricing guide.
- FDA. (2018). Patent expirations for albuterol products.
- FDA Guidance. (2014). Considerations for inhalation drug approval pathways.
[1] [2] [3] [4] [5]
